Insufficient scRNA-seq data for expression of MUL1 at single-cell level.
Insufficient scRNA-seq data for expression of MUL1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2391.69 | 1445 / 1445 | 100% | 40.51 | 183 / 183 |
ovary | 100% | 1693.54 | 180 / 180 | 100% | 44.95 | 430 / 430 |
prostate | 100% | 1974.35 | 245 / 245 | 100% | 59.40 | 502 / 502 |
kidney | 100% | 2029.73 | 89 / 89 | 100% | 62.24 | 900 / 901 |
breast | 100% | 1994.05 | 459 / 459 | 100% | 56.00 | 1116 / 1118 |
skin | 100% | 2481.23 | 1809 / 1809 | 100% | 79.17 | 471 / 472 |
liver | 100% | 1500.66 | 226 / 226 | 100% | 36.75 | 405 / 406 |
pancreas | 100% | 1196.63 | 327 / 328 | 100% | 56.67 | 178 / 178 |
brain | 100% | 1246.71 | 2630 / 2642 | 100% | 62.10 | 705 / 705 |
thymus | 100% | 1738.58 | 653 / 653 | 100% | 53.26 | 602 / 605 |
bladder | 100% | 2251.05 | 21 / 21 | 99% | 52.87 | 501 / 504 |
stomach | 100% | 1722.93 | 359 / 359 | 99% | 41.23 | 284 / 286 |
intestine | 100% | 2290.23 | 966 / 966 | 99% | 45.05 | 523 / 527 |
lung | 99% | 1579.94 | 575 / 578 | 100% | 48.22 | 1152 / 1155 |
uterus | 100% | 2146.96 | 170 / 170 | 99% | 54.34 | 454 / 459 |
adrenal gland | 100% | 2039.23 | 258 / 258 | 98% | 44.48 | 225 / 230 |
adipose | 100% | 1909.34 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1581.16 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 66.79 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 44.93 | 29 / 29 |
spleen | 100% | 1758.65 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 27.17 | 1 / 1 |
muscle | 100% | 2308.86 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 100% | 2066.66 | 858 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 54.32 | 44 / 45 |
peripheral blood | 86% | 1134.13 | 801 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1901028 | Biological process | regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
GO_0016567 | Biological process | protein ubiquitination |
GO_0016925 | Biological process | protein sumoylation |
GO_0006919 | Biological process | activation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0000266 | Biological process | mitochondrial fission |
GO_0010821 | Biological process | regulation of mitochondrion organization |
GO_0071650 | Biological process | negative regulation of chemokine (C-C motif) ligand 5 production |
GO_0090141 | Biological process | positive regulation of mitochondrial fission |
GO_0000209 | Biological process | protein polyubiquitination |
GO_1904925 | Biological process | positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization |
GO_1903861 | Biological process | positive regulation of dendrite extension |
GO_0031648 | Biological process | protein destabilization |
GO_0051898 | Biological process | negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0051881 | Biological process | regulation of mitochondrial membrane potential |
GO_0045824 | Biological process | negative regulation of innate immune response |
GO_0033235 | Biological process | positive regulation of protein sumoylation |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0050821 | Biological process | protein stabilization |
GO_0051646 | Biological process | mitochondrion localization |
GO_0010637 | Biological process | negative regulation of mitochondrial fusion |
GO_0006915 | Biological process | apoptotic process |
GO_0060339 | Biological process | negative regulation of type I interferon-mediated signaling pathway |
GO_0071360 | Biological process | cellular response to exogenous dsRNA |
GO_0050689 | Biological process | negative regulation of defense response to virus by host |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005777 | Cellular component | peroxisome |
GO_0043025 | Cellular component | neuronal cell body |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0030424 | Cellular component | axon |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0019789 | Molecular function | SUMO transferase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0002039 | Molecular function | p53 binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | MUL1 |
Protein name | Mitochondrial ubiquitin ligase activator of NFKB 1 (EC 2.3.2.27) (E3 SUMO-protein ligase MUL1) (E3 ubiquitin-protein ligase MUL1) (Growth inhibition and death E3 ligase) (Mitochondrial-anchored protein ligase) (Protein Hades) (Putative NF-kappa-B-activating protein 266) (RING finger protein 218) (RING-type E3 ubiquitin transferase NFKB 1) |
Synonyms | MULAN RNF218 GIDE C1orf166 MAPL |
Description | FUNCTION: Exhibits weak E3 ubiquitin-protein ligase activity . E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates . Can ubiquitinate AKT1 preferentially at 'Lys-284' involving 'Lys-48'-linked polyubiquitination and seems to be involved in regulation of Akt signaling by targeting phosphorylated Akt to proteasomal degradation . Mediates polyubiquitination of cytoplasmic TP53 at 'Lys-24' which targets TP53 for proteasomal degradation, thus reducing TP53 levels in the cytoplasm and mitochondrion . Proposed to preferentially act as a SUMO E3 ligase at physiological concentrations . Plays a role in the control of mitochondrial morphology by promoting mitochondrial fragmentation, and influences mitochondrial localization . Likely to promote mitochondrial fission through negatively regulating the mitochondrial fusion proteins MFN1 and MFN2, acting in a pathway that is parallel to the PRKN/PINK1 regulatory pathway . May also be involved in the sumoylation of the membrane fission protein DNM1L . Inhibits cell growth . When overexpressed, activates JNK through MAP3K7/TAK1 and induces caspase-dependent apoptosis . Involved in the modulation of innate immune defense against viruses by inhibiting RIGI-dependent antiviral response . Can mediate RIGI sumoylation and disrupt its polyubiquitination . . |
Accessions | ENST00000264198.5 Q969V5 |